CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
517.10MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.0350xvs all stocks
52-Week Change
216.86%vs all stocks
Market Capitalization
517.10MUSDvs all stocks (USD)
Enterprise Value
292.14MUSDvs all stocks (USD)
Forward P/E
-9.85xvs Biotechnology peers
Price to Book (MRQ)
2.39xvs Biotechnology peers
Enterprise to EBITDA
-3.59xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.39%vs Biotechnology peers
Return on Equity (TTM)
-40.96%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-81.44MUSDvs all stocks (USD)
Net Income (TTM)
-106.13MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-72.67MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-46.89MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-75.25MUSDvs all stocks (USD)
Pre-tax Income
-68.65MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-68.65MUSDFY2025 · Dec 31, 2025EBIT
-75.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-75.20MUSDFY2025 · Dec 31, 2025Research & Development
42.08MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.16MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.34MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.06USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.06USDFY2025 · Dec 31, 2025Basic Shares Outstanding
94.16MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
94.16MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-68.65MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
30.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-57.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-57.19MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
109.41MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-68.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
49.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.33MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-814.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-113.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-113.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-7.37MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.27MUSDFY2025 · Dec 31, 2025Shares Outstanding
94.88MSharesUpdated Jul 19, 2026Float Shares
50.84MSharesUpdated Jul 19, 2026Shares Short
9.24MSharesUpdated Jul 19, 2026Short Ratio
5.51daysvs all stocks
Short % of Shares Outstanding
13.03%vs all stocks
% Held by Insiders
21.51%vs all stocks
% Held by Institutions
78.86%vs all stocks
Total Cash (MRQ)
225.59MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.38USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
19.33xvs Biotechnology peers
Book Value per Share (MRQ)
2.28USDUpdated Jul 19, 2026Total Assets
113.95MUSDvs all stocks (USD)
Total Current Assets
112.31MUSDFY2025 · Dec 31, 2025Total Liabilities
12.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
12.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
109.41MUSDFY2025 · Dec 31, 2025Accounts Payable
1.28MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-224.55MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
101.54MUSDvs all stocks (USD)
52-Week Low
1.34USDUpdated Jul 19, 202652-Week High
7.44USDUpdated Jul 19, 202652-Week Change
216.86%vs all stocks
Beta
-0.0350xvs all stocks
50-Day MA
4.50USDUpdated Jul 19, 2026200-Day MA
4.92USDUpdated Jul 19, 2026Avg 10-Day Volume
994.49KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.52MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.09USDUpdated Jul 19, 2026Other Income / Expense
260.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule